Table 1.

Details of curcumin clinical studies.

Number	Status	ID	Phase	Study Start Date	Study Completion Date	Sponsor	Condition or Disease	Number of Participants	Intervention/Treatment	Research Endpoint
1	Completed	NCT00192842	2	Jul-04	Sep-10	Rambam Health Care Campus	Advanced Pancreatic Cancer	17	Curcumin 8 g po qd (+gemcitabine)	To assess the efficacy of the standard chemotherapy gemcitabine plus curcumin in patients with advanced pancreatic cancer.
2	Completed	NCT00094445	2	Nov-04	Apr-14	M.D. Anderson Cancer Center	Advanced Pancreatic Cancer	50	Curcumin 8 g po qd for 22 weeks	To learn if treatment with curcumin can help slow the growth of pancreatic cancers and to access the safety.
3	Completed	NCT00113841	-	Nov-04	Aug-09	M.D. Anderson Cancer Center	Patients With Multiple Myeloma	42	Curcumin 2 g po bid (+Bioperine 5 mg po bid)	To assess the Quality of life (QOL).
4	Completed	NCT03211104	-	Aug-07	Aug-15	Samsung Medical Center	Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy	107	Curcumin 240 mg po tid for 6 month	To assess whether curcumin influences the duration of treatment interruption and rate of prostatic specific antigen (PSA) progression.
5	Recruiting	NCT00745134	2	Aug-08	Mar-23	M.D. Anderson Cancer Center	Rectal Cancer	45	Curcumin po bid +(Radiation therapy and capecitabine) for 11.5 weeks	To asscess if curcumin can make tumor cells more sensitive to radiation therapy.
6	Completed	NCT01160302	1	Jun-10	Jan-16	Louisiana State University Health Sciences Center Shreveport	Head and Neck Cancer	33	Microgranular Curcumin C3 Complex® 4 g po bid for 21–28 days	To assess the adverse effects.
7	Completed	NCT01333917	1	Nov-10	Jan-13	University of North Carolina, Chapel Hill	People with positive colonoscopy screening	40	Curcumin C3 4 g qd for 30 days	To identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies, and also to evaluate the tolerability and toxicity.
8	Completed	NCT01917890	-	Mar-11	Oct-13	Shahid Beheshti University of Medical Sciences	Prostate Cancer	40	Curcumin or placebo (500 mg po qd for 7–8 weeks)	To assess Progression free survival, Time to Disease Progression and Time to treatment failure.
9	Completed	NCT01490996	2	Feb-12	May-17	University of Leicester	Inoperable Colorectal Cancer	41	Curcumin C3 2 g po qd (+FOLFOX)	To assess the safety, tolerability, efficacy(measured by response rate with RECIST and overall survival in months).
10	Completed	NCT01740323	2	May-15	Jul-18	Emory University	Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy	30	Curcumin or placebo (500 mg po bid)	To assess if curcumin reduces NF-kB DNA binding and its downstream mediator IL-6.
11	Completed	NCT02439385	2	Aug-15	Aug-19	Gachon University Gil Medical Center	Colorectal Cancer Patients With Unresectable Metastasis	44	Curcumin 100mg po bid (+Avastin/FOLFIRI)	To assess Progression free survival, Overall survival rate, Overall response rate, safety and fatigue score.
12	Completed	NCT02321293	1	Aug-15	Dec-16	Lady Davis Institute	EGFR -Mutant Advanced NSCLC	20	Longvida® Optimized Curcumin 80 mg po qd (+Tyrosine Kinase Inhibitor) last for 8 weeks	To assess the safety and tolerability.
13	Recruiting	NCT02724202	1	Mar-16	-	Baylor Research Institute	Colon Cancer	13	Curcumin 500 mg po bid for 2 weeks. (Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5-Fu)	To test the safety, effects and find the Response Rate.
14	Completed	NCT03072992	2	Mar-17	Jun-19	National Center of Oncology, Armenia	Advanced Breast Cancer	150	Paclitaxel +(curcumin or placebo) (300 mg i.v. once weekly for 12 weeks.)	To assess the adverse effects, Quality of life, Progression free survival, Time to Disease Progression, and Time to treatment failure.
15	Completed	NCT03534024	-	Aug-18	-	National Nutrition and Food Technology Institute	Metabolic Syndrome	50	Nanomicielle curcumin or placebo	To determine the effects of nanomicelle curcumin on glycemic control, serum lipid profile, blood pressure and anthropometric measurements
16	Recruiting	NCT03769766	3	Mar-19	-	University of Texas Southwestern Medical Center	Prostate Cancer	291	Curcumin or placebo (500 mg po bid)	To assess the efficacy.
17	Recruiting	NCT03980509	1	Jan-20	-	Medical University of South Carolina	Invasive Breast Cancer	20	Curcumin 500 mg po bid. (Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.)	To determine whether curcumin causes biological changes in primary tumors of breast cancer patients.
18	Not yet recruiting	NCT04294836	2	Dec-21	-	Instituto Nacional de Cancerologia, Columbia	Cervical Cancer	240	Cisplatin plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) or placebo 2000 mg daily (each 6 h)	To assess the efficacy and safety.